KRAS and cancer: Notably, the MATCH Subprotocol I is investigating taselisib in solid tumors harboring PIK3CA mutations without KRAS mutations or PTEN loss, while the MATCH Subprotocol Z1F is assessing copanlisib in PIK3CA-mutated cancers with primary efficacy analysis (n = 25) showing ORR of 16% (90% CI: 6–33), mPFS of 3.4 months (90% CI: 1.8–6.6), and mOS of 5.9 months (90% CI: 4.9–13.7) [86].